Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24566078 | 0.95 | DHFR (0.50) | DHFRCRHBPCRHR2SMN1; SMN2HRH4 | |
| SCHEMBL24566086 | 0.79 | DHFR (0.51) | DHFRCRHBPCRHR2SMN1; SMN2NUDT1 | |
| SCHEMBL6700853 | 0.72 | DHFR (0.58) | DHFRHRH4LMNA | |
| Water SCHEMBL11002492 | 0.71 | DHFR (0.56) | DHFRHRH4LMNA | |
| SCHEMBL21325614 | 0.69 | ALDH1A1 (0.51) | SMN1; SMN2HRH4 | |
| SCHEMBL16040932 | 0.68 | GAA (0.33) | CRHBPCRHR2SMN1; SMN2HRH4CYP1A2 | |
| SCHEMBL17979709 | 0.68 | CHRM3 (0.46) | CRHBPCRHR2SMN1; SMN2HRH4NUDT1 | |
| SCHEMBL5788921 | 0.67 | CRHBP (0.96) | CRHBPCRHR2SMN1; SMN2HRH4NUDT1 | |
| SCHEMBL17979711 | 0.67 | CHRM3 (0.49) | CRHBPCRHR2SMN1; SMN2NUDT1CYP1A2 | |
| SCHEMBL17822435 | 0.67 | CTSK (0.52) | CRHBPCRHR2SMN1; SMN2HRH4NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |